Human CSF2 recombinant protein (Native)

Cat.#: 514746

Size:

Special Price 474.3 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Human CSF2 recombinant protein (Native)
  • Documents
  • Description
    Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.Immune Checkpoint Immunotherapy Cancer Immunotherapy Targeted Therapy
  • Protein name
    Granulocyte-macrophage colony-stimulating factor
  • Protein short names
    GM-CSF,GMCSF
  • Uniprot ID
    P04141
  • Gene Name
    Granulocyte-macrophage colony-stimulating factor; GM-CSF; Colony-stimulating factor; CSF; Molgramostin; Sargramostim
  • Source/Expression Host
    Human Cells
  • Expression Plasmid/cDNA
    A DNA sequence encoding human GMCSF (NP_000749.2) (Met1-Glu144) was expressed.
  • Protein Species
    Human
  • Molecular weight
    The recombinant human GMCSF consists of 127 amino acids and predicts a molecular mass of 14.5 kDa.
  • Purity
    > 95 % as determined by SDS-PAGE
  • Validations

    Human GM-CSF/CSF2 Protein 15484

    Human GM-CSF/CSF2 Protein 15484

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"